This cohort study investigates the comparative risks of male external genital infections in adult male patients with type 2 diabetes treated with sodium-glucose cotransporter 2 (SGLT2) inhibitors vs glucagon-like peptide-1 receptor agonists (GLP-1RAs). Here, GLP1R is linked to type 2 diabetes mellitus.